LILRB4 and plasma cell myeloma: Little is known whether BTZ can inhibit bone damage in multiple myeloma with the depletion of LILRB4. KMS26-LILRB4-WT or -KO cells were injected into NSG mice by tail vein, and BTZ or PBS was used to treat xenograft models twice a week (Fig. 6A).